We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Process Validation Should Encompass Complete Lifecycle of Drug, EMA Says
Process Validation Should Encompass Complete Lifecycle of Drug, EMA Says
May 10, 2012
Drugmakers should apply a lifecycle approach to process validation — tying together data on product and process development, the commercial manufacturing process and maintenance and consistency of the process during routine commercial production, according to the European Medicines Agency (EMA). Includes the full text of EMA Draft Guideline On Process Validation for Drugmakers.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor